PT - JOURNAL ARTICLE AU - Pak, Andrew AU - Chang, Emiley TI - Amantadine withdrawal in a patient with spinocerebellar ataxia AID - 10.1136/bcr-2023-256840 DP - 2023 Nov 01 TA - BMJ Case Reports PG - e256840 VI - 16 IP - 11 4099 - http://casereports.bmj.com/content/16/11/e256840.short 4100 - http://casereports.bmj.com/content/16/11/e256840.full SO - BMJ Case Reports2023 Nov 01; 16 AB - We report a case of a man with spinocerebellar ataxia (SCA) on high-dose amantadine who was admitted for acute on chronic dysphagia secondary to progression of SCA. Four days after oral medications were held due to patient’s dysphagia, he developed fever, tachycardia and mild rigidity in extremities and became obtunded. Despite antibiotics treatment, the vitals and mental status changes persisted for 8 days. When amantadine was resumed, the patient’s vital signs and encephalopathy improved within 2 days. This is among the first reports of amantadine withdrawal syndrome (AWS) in a patient without Parkinson’s disease. Our case reinforces the importance of careful medication review at admission and consideration of pharmacologic side effects with not only medication initiation but also discontinuation.